ICON Public FY2024 EPS Forecast Raised by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR) – Equities research analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for ICON Public in a research note issued to investors on Tuesday, January 14th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will earn $13.40 per share for the year, up from their prior estimate of $13.25. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share.

ICLR has been the topic of several other reports. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research report on Tuesday. Redburn Atlantic started coverage on ICON Public in a report on Monday, October 14th. They set a “neutral” rating and a $311.00 target price on the stock. Truist Financial reissued a “buy” rating and issued a $284.00 price target (down from $295.00) on shares of ICON Public in a report on Wednesday, December 18th. Royal Bank of Canada restated an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research report on Wednesday. Finally, Baird R W lowered shares of ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Trading Down 0.4 %

Shares of ICON Public stock opened at $199.47 on Thursday. The stock has a market cap of $16.46 billion, a PE ratio of 22.24, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20. The firm has a fifty day moving average price of $210.79 and a 200 day moving average price of $270.01. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the company posted $3.10 EPS. ICON Public’s quarterly revenue was down 1.2% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Icon Wealth Advisors LLC increased its stake in ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares in the last quarter. Foyston Gordon & Payne Inc acquired a new stake in shares of ICON Public in the third quarter worth approximately $11,672,000. GAMMA Investing LLC increased its position in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares in the last quarter. Sara Bay Financial purchased a new stake in shares of ICON Public during the third quarter worth approximately $1,143,000. Finally, First Horizon Advisors Inc. raised its stake in ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.